Table 1.
Demographics and Key Baseline Characteristics
| Characteristics | AMG 102 10 mg/kg n = 40 | AMG 102 20 mg/kg n = 20 | All Enrolled Patients N = 60a |
|---|---|---|---|
| Sex, n (%) | |||
| Women | 15 (38) | 7 (35) | 22 (37) |
| Men | 25 (63) | 13 (65) | 38 (63) |
| Race, n (%) | |||
| White | 36 (90) | 18 (90) | 54 (90) |
| Black | 3 (8) | 0 (0) | 3 (5) |
| Hispanic | 1 (3) | 1 (5) | 2 (3) |
| Asian | 0 (0) | 1 (5) | 1 (2) |
| Age, median (range) | 54 (19–71) | 54 (26–71) | 54 (19–71) |
| Karnofsky performance status, n (%) | |||
| 100 | 1 (3) | 1 (5) | 2 (3) |
| 90 | 18 (45) | 7 (35) | 25 (42) |
| 80 | 14 (35) | 7 (35) | 21 (35) |
| 70 | 4 (10) | 3 (15) | 7 (12) |
| 60 | 3 (8) | 2 (10) | 5 (8) |
| Histologic type for primary tumor, n (%) | |||
| Glioblastoma multiforme | 38 (95) | 20 (100) | 58 (97) |
| Low-grade gliomab | 1 (3) | 0 (0) | 1 (2) |
| Other | 1 (3) | 0 (0) | 1 (2) |
| Months since initial diagnosis,c | |||
| median (range) | 16 (3.9–78) | 14 (1–40) | 16 (1–78) |
| Prior therapies,dn (%) | |||
| 0 | 0 (0) | 0 (0) | 0 (0) |
| 1 | 11 (28) | 3 (15) | 14 (23) |
| 2 | 13 (33) | 9 (45) | 22 (37) |
| ≥3 | 16 (40) | 8 (40) | 24 (40) |
| Prior radiotherapy, n (%) | |||
| 0 | 1 (3) | 0 (0) | 1 (2) |
| 1 | 33 (85) | 19 (95) | 52 (87) |
| 2 | 5 (13) | 1 (5) | 6 (10) |
| ≥3 | 1 (3) | 0 (0) | 1 (2) |
| Prior VEGF pathway inhibitors, n (%) | |||
| Bevacizumab | 19 (48) | 10 (50) | 29 (48) |
| Aflibercept | 3 (8) | 1 (5) | 4 (7) |
| Sorafenib | 0 (0) | 2 (10) | 2 (3) |
| Pazopanib | 1 (3) | 0 (0) | 1 (2) |
| Vandetanib | 1 (3) | 0 (0) | 1 (2) |
| Vatalanib | 1 (3) | 0 (0) | 1 (2) |
| Prior surgery,en (%) | 40 (100) | 20 (100) | 60 (100) |
aPatients who received ≥1 dose of AMG 102.
bEnrollment of the patient with low-grade disease was a protocol violation.
cDate of enrollment minus date of primary diagnosis.
dIncludes chemotherapy, immunotherapy, hormonal therapy, targeted biologics, small-molecule inhibitors, vaccines, and others.
ePrior surgery includes biopsy and resection procedures.